Patents by Inventor Vuk Koprivica

Vuk Koprivica has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHODS OF TREATING PDE IV-MEDIATED DISEASES OR CONDITIONS
    Publication number: 20230364100
    Abstract: The disclosure provides methods and compositions for the treatment of PDE IV-mediated diseases or conditions, including inflammatory diseases or conditions, using a compound of Formula (I) or a pharmaceutically acceptable salt thereof:
    Type: Application
    Filed: September 10, 2021
    Publication date: November 16, 2023
    Applicant: Vanda Pharmaceuticals, Inc.
    Inventor: Vuk KOPRIVICA
  • EGFR inhibitors promote axon regeneration
    Patent number: 8142782
    Abstract: Compositions and methods for promoting neural regeneration in a patient determined to have a lesion in a mature CNS neuron are disclosed. The method comprises the step of contacting the neuron with an EGFR inhibitor sufficient to promote regeneration of the neuron.
    Type: Grant
    Filed: February 18, 2009
    Date of Patent: March 27, 2012
    Assignee: Children's Medical Center Corporation
    Inventors: Zhigang He, Vuk Koprivica
  • EGFR inhibitors promote axon regeneration
    Patent number: 7959901
    Abstract: Compositions and methods for promoting neural regeneration in a patient determined to have a lesion in a mature CNS neuron are disclosed. The method comprises the step of contacting the neuron with an EGFR inhibitor sufficient to promote regeneration of the neuron.
    Type: Grant
    Filed: February 6, 2008
    Date of Patent: June 14, 2011
    Assignee: Children's Medical Center Corporation
    Inventors: Zhigang He, Vuk Koprivica
  • Reducing myelin-mediated inhibition of axon regeneration
    Patent number: 7691590
    Abstract: Oligodendrocyte-myelin glycoprotein (OMgp)-specific binding agents are used to reduce OMgp-mediated axon growth inhibition. Mixtures of axons and OMgp and mixtures of Nogo receptor (NgR) and OMgp are used in pharmaceutical screens to characterize agents as inhibiting binding of NgR to OMgp and promoting axon regeneration.
    Type: Grant
    Filed: December 18, 2007
    Date of Patent: April 6, 2010
    Assignee: Children's Medical Center Corporation
    Inventors: Zhigang He, Kevin C. Wang, Vuk Koprivica, Jieun A. Kim
  • Axon Regeneration with PKC Inhibitors
    Publication number: 20090220570
    Abstract: Regenerative growth of an adult mammalian central nervous system neuron axon subject to growth inhibition by endogenous, myelin growth repulsion factors is promoted by delivering to the axon a therapeutically effective amount of a specific inhibitor of protein kinase C, whereby regenerative growth of the axon is promoted and a resultant promotion of the regenerative growth of the axon is detected.
    Type: Application
    Filed: May 18, 2009
    Publication date: September 3, 2009
    Inventors: Zhigang He, Vuk Koprivica, Rajeev Sivasankanan
  • EGFR INHIBITORS PROMOTE AXON REGENERATION
    Publication number: 20090148494
    Abstract: Compositions and methods for promoting neural regeneration in a patient determined to have a lesion in a mature CNS neuron are disclosed. The method comprises the step of contacting the neuron with an EGFR inhibitor sufficient to promote regeneration of the neuron.
    Type: Application
    Filed: February 18, 2009
    Publication date: June 11, 2009
    Inventors: Zhigang He, Vuk Koprivica
  • EGFR inhibitors promote axon regeneration
    Patent number: 7449442
    Abstract: Compositions and methods for promoting neural regeneration in a patient determined to have a lesion in a mature CNS neuron are disclosed. The method comprises the step of contacting the neuron with an EGFR inhibitor sufficient to promote regeneration of the neuron.
    Type: Grant
    Filed: July 12, 2005
    Date of Patent: November 11, 2008
    Assignee: Children's Medical Center Corporation
    Inventors: Zhigang He, Vuk Koprivica
  • Reducing Myelin-Mediated Inhibition of Axon Regeneration
    Publication number: 20080188411
    Abstract: Oligodendrocyte-myelin glycoprotein (OMgp)-specific binding agents are used to reduce OMgp-mediated axon growth inhibition. Mixtures of axons and OMgp and mixtures of Nogo receptor (NgR) and OMgp are used in pharmaceutical screens to characterize agents as inhibiting binding of NgR to OMgp and promoting axon regeneration.
    Type: Application
    Filed: December 18, 2007
    Publication date: August 7, 2008
    Inventors: Zhigang He, Kevin C. Wang, Vuk Koprivica, Jieun A. Kim
  • EGFR inhibitors promote axon regeneration
    Publication number: 20080145314
    Abstract: Compositions and methods for promoting neural regeneration in a patient determined to have a lesion in a mature CNS neuron are disclosed. The method comprises the step of contacting the neuron with an EGFR inhibitor sufficient to promote regeneration of the neuron.
    Type: Application
    Filed: February 6, 2008
    Publication date: June 19, 2008
    Inventors: Zhigang He, Vuk Koprivica
  • Reducing myelin-mediated inhibition of axon regeneration
    Patent number: 7309485
    Abstract: Oligodendrocyte-myelin glycoprotein (OMgp)-specific binding agents are used to reduce OMgp-mediated axon growth inhibition. Mixtures of axons and OMgp and mixtures of Nogo receptor (NgR) and OMgp are used in pharmaceutical screens to characterize agents as inhibiting binding of NgR to OMgp and promoting axon regeneration.
    Type: Grant
    Filed: April 19, 2002
    Date of Patent: December 18, 2007
    Assignee: Children's Medical Center Corporation
    Inventors: Zhigang He, Kevin C. Wang, Vuk Koprivica, Jieun A. Kim
  • EGFR inhibitors promote axon regeneration
    Publication number: 20070014792
    Abstract: Compositions and methods for promoting neural regeneration in a patient determined to have a lesion in a mature CNS neuron are disclosed. The method comprises the step of contacting the neuron with an EGFR inhibitor sufficient to promote regeneration of the neuron.
    Type: Application
    Filed: July 12, 2005
    Publication date: January 18, 2007
    Inventors: Zhigang He, Vuk Koprivica
  • Axon regeneration with PKC inhibitors
    Publication number: 20050130877
    Abstract: Regenerative growth of an adult mammalian central nervous system neuron axon subject to growth inhibition by endogenous, myelin growth repulsion factors is promoted by delivering to the axon a therapeutically effective amount of a specific inhibitor of protein kinase C, whereby regenerative growth of the axon is promoted and a resultant promotion of the regenerative growth of the axon is detected.
    Type: Application
    Filed: November 9, 2004
    Publication date: June 16, 2005
    Inventors: Zhigang He, Vuk Koprivica, Rajeev Sivasankaran
  • Axon regeneration with PKC inhibitors
    Patent number: 6815450
    Abstract: Regenerative growth of an adult mammalian central nervous system neuron axon subject to growth inhibition by endogenous, myelin growth repulsion factors is promoted by delivering to the axon a therapeutically effective amount of a specific inhibitor of protein kinase C, whereby regenerative growth of the axon is promoted and a resultant promotion of the regenerative growth of the axon is detected.
    Type: Grant
    Filed: March 14, 2003
    Date of Patent: November 9, 2004
    Assignee: Children's Medical Center Corporation
    Inventors: Zhigang He, Vuk Koprivica, Rajeev Sivasankaran
  • Axon regeneration with PKC inhibitiors
    Patent number: 6664266
    Abstract: Regenerative growth of an adult mammalian central nervous system neuron axon subject to growth inhibition by endogenous, myelin growth repulsion factors is promoted by delivering to the axon a therapeutically effective amount of a specific inhibitor of protein kinase C, whereby regenerative growth of the axon is promoted and a resultant promotion of the regenerative growth of the axon is detected.
    Type: Grant
    Filed: March 14, 2002
    Date of Patent: December 16, 2003
    Assignee: Children's Medical Center Corporation
    Inventors: Zhigang He, Vuk Koprivica, Rajeev Sivasankaran
  • Axon regeneration with PKC inhibitors
    Publication number: 20030176424
    Abstract: Regenerative growth of an adult mammalian central nervous system neuron axon subject to growth inhibition by endogenous, myelin growth repulsion factors is promoted by delivering to the axon a therapeutically effective amount of a specific inhibitor of protein kinase C, whereby regenerative growth of the axon is promoted and a resultant promotion of the regenerative growth of the axon is detected.
    Type: Application
    Filed: March 14, 2003
    Publication date: September 18, 2003
    Applicant: Children's Medical Center Corporation
    Inventors: Zhigang He, Vuk Koprivica, Rajeev Sivasankaran
  • AXON REGENERATION WITH PKC INHIBITIORS
    Publication number: 20030176423
    Abstract: Regenerative growth of an adult mammalian central nervous system neuron axon subject to growth inhibition by endogenous, myelin growth repulsion factors is promoted by delivering to the axon a therapeutically effective amount of a specific inhibitor of protein kinase C, whereby regenerative growth of the axon is promoted and a resultant promotion of the regenerative growth of the axon id detected.
    Type: Application
    Filed: March 14, 2002
    Publication date: September 18, 2003
    Applicant: Children's Medical Center Corporation
    Inventors: Zhigang He, Vuk Koprivica, Rajeev Sivasankaran
  • Reducing myelin-mediated inhibition of axon regeneration
    Publication number: 20030113325
    Abstract: Oligodendrocyte-myelin glycoprotein (OMgp)-specific binding agents are used to reduce OMgp-mediated axon growth inhibition. Mixtures of axons and OMgp and mixtures of Nogo receptor (NgR) and OMgp are used in pharmaceutical screens to characterize agents as inhibiting binding of NgR to OMgp and promoting axon regeneration.
    Type: Application
    Filed: December 3, 2001
    Publication date: June 19, 2003
    Inventors: Zhigang He, Kevin C. Wang, Vuk Koprivica, Jieun A. Kim
  • Reducing myelin-mediated inhibition of axon regeneration
    Publication number: 20030113326
    Abstract: Oligodendrocyte-myelin glycoprotein (OMgp)-specific binding agents are used to reduce OMgp-mediated axon growth inhibition. Mixtures of axons and OMgp and mixtures of Nogo receptor (NgR) and OMgp are used in pharmaceutical screens to characterize agents as inhibiting binding of NgR to OMgp and promoting axon regeneration.
    Type: Application
    Filed: April 19, 2002
    Publication date: June 19, 2003
    Applicant: Children's Medical Center Corporation
    Inventors: Zhigang He, Kevin C. Wang, Vuk Koprivica, Jieun A. Kim